Wed Dec 11, 2019, 07:24 AM
|
|
Member
|
|
Join Date: Feb 2016
Location: New Jersey
Posts: 18
|
|
Quote:
Originally Posted by maggiemag
Hi everyone! You may already know this, but the drug Luspatercept has been FDA approved for treatment in beta thalassemia. Nope, not for low/intermediate risk MDS yet, but it’s approval for the one disease is very encouraging, I think. It has been shown to decrease transfusion dependence significantly in MDS. I think the target approval for MDS is April, 2020. So not that much longer to wait! It primarily was studied, I believe, for those MDS patients who have ring sideroblasts. I do not have those, so wonder if it will be strictly enforced. I asked my physician about that, and she thought there might be a way. We shall see! At any rate, we have some good news for a change.
|
Your post started us looking and the first group of posts at the link below are reports about Luspatercept from the very recent ASH conference.
http://acceleronpharma.com/science-p.../luspatercept/ |